Breast CT Authority and Head of Clinical Trials Joins Izotropic
Breast CT Authority and Head of Clinical Trials Joins Izotropic
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, is pleased to announce the addition of Dr. Shadi Aminololama- Shakeri, MD, FSBI to its advisory board and commercialization team as a clinical consultant.
温哥华,不列颠哥伦比亚省-(Newsfile Corp.-2022年3月14日)-Izotrotic公司(CSE:以藏)(OTCQB:IZOZF)(FSE:1R3)("各向同性“或”公司为了更准确地检测和诊断乳腺癌,一家将专用乳腺CT(计算机断层扫描)成像平台IzoView商业化的公司高兴地宣布,Shadi Aminololama-Shakeri博士,MD,FSBI加入其顾问委员会和商业化团队,担任临床顾问。
Dr. Shakeri is the Chief of the Division of Breast Radiology at the University of California Davis Medical Center (UC Davis) where Izotropic's technology founder, Dr. John M. Boone, has developed four successive breast CT imaging devices that have been used in clinical studies for academic and research purposes[1]. Dr. Shakeri specializes in breast imaging and has been in charge of the clinical aspects of Breast CT clinical trials since 2017 at UC Davis and has been working with Dr. Boone on breast CT since 2009. Her work has included clinical study design, recruiting, speaking to patients, and viewing and evaluating breast CT images, making her a unique authority on the capabilities and validity of breast CT technology.
Shakeri博士是加州大学戴维斯医学中心(UC Davis)乳房放射科主任,该中心的技术创始人John M.Boone博士开发了四种连续的乳腺CT成像设备,已用于临床研究和学术目的[1]。Shakeri博士专门从事乳房成像,自2017年以来一直在加州大学戴维斯分校负责乳房CT临床试验的临床方面,并自2009年以来一直与Boone博士合作研究乳房CT。她的工作包括临床研究设计、招募、与患者交谈以及查看和评估乳腺CT图像,使她成为乳房CT技术能力和有效性的独特权威。
Now that the most recent clinical trial at UC Davis comparing contrast-enhanced fourth-generation breast CT to contrast-enhanced MRI has entered the data analysis phase, Dr. Shakeri is now able to collaborate with Izotropic as a clinical authority on breast CT and participate in meetings and key presentations to the radiology and investment communities.
加州大学戴维斯分校最新的对比增强第四代乳房CT和增强MRI的临床试验已经进入数据分析阶段,Shakeri博士现在可以作为乳房CT的临床权威与Izotroal合作,并参加放射学和投资界的会议和重要报告。
"I will say that in my clinical experience with the first four generations of contrast-enhanced breast CT device, the technology brings all of the advantages of breast MRI, which has been shown by numerous studies to be superior to mammograms and ultrasound combined in detecting breast cancer, yet it is significantly faster, and open in design so there are no issues with claustrophobia or breast compression. I am excited about sharing data and breast CT images from trials undertaken at UC Davis with the radiology community," said Dr. Shakeri.
“我想说的是,在我使用前四代对比度增强乳腺CT设备的临床经验中,这项技术带来了乳腺MRI的所有优势,大量研究表明,在检测乳腺癌方面,它比乳房X光检查和超声波联合检测要好得多,但它的速度要快得多,而且在设计上是开放的,所以不会出现幽闭恐惧症或乳房压缩的问题。我很高兴能与放射科社区分享在加州大学戴维斯分校进行的试验的数据和乳腺CT图像,”沙克里博士说。
"I anticipate Izotropic's fifth-generation device, IzoView, to be superior in design and overall image quality when compared to the fourth-generation device and have less ownership cost than an MRI and thereby much more accessible to have in the clinic in urban or rural settings.
我预计,与第四代设备相比,Izotroy公司的第五代设备IzoView将在设计和整体图像质量方面更好,并且拥有成本比核磁共振更低,因此在城市或农村的诊所中更容易获得。
"Based on my overall experience with the four UC Davis contrast-enhanced Breast CT prototypes, this will be an important tool for breast imagers in detecting breast cancer. Cancers light up and stand out compared to non-contrast imaging. Breast CT with contrast has the potential to replace most conventional non-contrast-enhanced imaging modalities for diagnostic assessment. Today's standard of care could include multiple mammography, tomosynthesis, and ultrasound images compared to one Breast CT scan that takes about 10 seconds. Given that I expect IzoView to be an improvement over the fourth-generation device, I am very excited to see IzoView's demonstration of superiority to non-contrast-enhanced imaging in Izotropic's upcoming clinical study."
根据我对四个加州大学戴维斯分校增强的乳腺CT原型的总体经验,这将是乳房成像仪检测乳腺癌的一个重要工具。与非对比度成像相比,癌症变得明亮和突出。乳腺CT增强扫描有可能取代大多数常规的非增强扫描成像方法,用于诊断评估。今天的标准护理可能包括多次乳房X光检查、断层合成和超声波图像,而一次乳房CT扫描需要大约10秒。鉴于我预计IzoView将是对第四代设备的改进,我非常兴奋地看到IzoView在Izotroy即将进行的临床研究中展示了相对于非对比度增强成像的优势。“
Dr. Shakeri will also be contributing to Izotropic's awareness efforts by commenting on and discussing published information and facts from previous and ongoing UC Davis breast CT clinical trials. For updates, please follow Izotropic's Twitter account here and Dr. Shakeri's Twitter account here.
Shakeri博士还将通过评论和讨论以前和正在进行的加州大学戴维斯分校乳房CT临床试验中发表的信息和事实,为提高Izotroy公司的认识做出贡献。有关最新消息,请关注Izotroy的Twitter账户此处和Shakeri博士的Twitter账户此处。
"Dr. Shakeri has her finger on the pulse of the capabilities of Breast CT and the breast imaging care needs of patients, referring physicians, radiologists and breast imaging clinics," said CEO Dr. John McGraw. "She has already been a key contributor to our review panels with EXCITE International, as her breadth of experience and clinical knowledge is invaluable. We look forward to working with Dr. Shakeri as we expedite provider and patient access to IzoView Breast CT and future platform products."
首席执行官约翰·麦格劳博士说:“Shakeri博士对乳腺CT的能力和患者的乳房成像护理需求了如指掌,涉及内科医生、放射科医生和乳房成像诊所。她已经是我们Excite International审查小组的关键贡献者,因为她丰富的经验和临床知识是无价的。我们期待着与Shakeri博士合作,因为我们加快了供应商和患者对IzoView乳房CT和未来平台产品的访问。“
Stock Options
股票期权
The Company has granted Dr. Shakeri 100,000 stock options at an exercise price of $0.65. The stock options are in effect for five (5) years and vest immediately.
该公司已授予Shakeri博士10万股股票期权,行权价为0.65美元。股票期权的有效期为五(5)年,并立即授予。
About Dr. Shakeri
关于Shakeri博士
Dr. Shakeri is a fellowship-trained radiologist specializing in breast imaging, including digital mammography, tomosynthesis, breast computed tomography, ultrasound, and magnetic resonance imaging. She practices and offers imaging-guided care for all aspects of breast conditions and routinely performs breast procedures using ultrasound guidance, MRI localization, and stereotactic triangulation techniques. She emphasizes individualized breast care plans for maintaining breast health.
Shakeri博士是一名训练有素的放射科医生,专门从事乳房成像,包括数字乳房X光照相、断层合成、乳房计算机断层扫描、超声波和磁共振成像。她为乳房疾病的各个方面提供并提供成像指导的护理,并定期使用超声引导、MRI定位和立体定向三角测量技术进行乳房手术。她强调个性化的乳房护理计划,以保持乳房健康。
Dr. Shakeri's research interests have focused on advancing imaging of suspicious breast lesions by dedicated breast CT developed at UC Davis by principal founder Dr. John Boone and numerous graduate students in the Department of Radiology.
Shakeri博士的研究兴趣主要集中在通过加州大学戴维斯分校的主要创始人John Boone博士和放射科的许多研究生开发的专用乳腺CT来推进可疑乳腺病变的成像。
ON BEHALF OF THE BOARD
我代表董事会
For investor relations inquiries, contact:
如需投资者关系咨询,请联系:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
詹姆斯·贝拉德
电子邮件:jberard@izocorp.com
电话:778-228-2314
免费电话:1-833-IZOCORP分机1
About Izotropic Corporation
关于Izotroy公司
Izotropic Corporation is the only publicly-traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
Izotroy公司是唯一一家将专用乳腺CT成像平台IzoView商业化的上市公司,该平台用于更准确地检测和诊断乳腺癌。为了加快患者和供应商使用IzoView的速度,Izotroy的初步临床研究打算证明诊断性乳房CT成像的性能优于诊断性乳房X光检查程序,并将于2022年第二季度启动。在后续的临床研究中,Izotrotic公司打算验证平台应用,包括放射学中的乳房筛查、外科肿瘤学中的治疗计划和监测,以及整形和重建外科中的乳房重建和植入物监测。
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
欲了解有关Izotroy公司的更多信息,请访问公司网站:izocorp.com,或查看公司在SEDAR上的简介:sedar.com。
Forward-Looking Statements
前瞻性陈述
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
本文档可能包含“前瞻性陈述”,这些陈述基于对公司管理层、业务的当前估计、假设、预测和预期,以及对公司运营所处的相关市场和经济环境的了解。在可能的情况下,本公司已尝试通过使用下列词语来识别此类信息和陈述:“预期”、“相信”、“设想”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“项目”、“目标”、“潜在”、“将”、“将”、“可能”、“可能”、“应该”、“继续,关于未来事件、趋势或前景或未来经营或财务业绩的任何讨论,“考虑”及其他类似表述及其派生,尽管并不是所有前瞻性表述都包含这些识别词语。这些陈述不是对业绩的保证,涉及难以控制或预测的风险和不确定因素,因此,它们可能导致公司未来活动的结果与此类陈述的内容和影响大不相同。前瞻性陈述仅在作出之日起具有相关性,公司没有义务更新或修改任何前瞻性陈述,以反映新的信息或未来事件或情况的发生,除非法律另有要求。本公司及其股东、高级管理人员和顾问均不对任何人根据本文所含信息采取的任何行动及其结果负责,包括但不限于购买或出售公司证券。本文档中的任何内容都不应被视为任何类型的医疗或其他建议。所有图片仅用于说明目的。IzoView尚未获准出售。
[1] Izotropic notes that the 5th generation breast CT device, IzoView being developed for commercialization has not undertaken the required clinical study for market authorization in the United States as of the date of this news release, and is not yet approved for sale in the United States.
[1]Izotrotic指出,5这是作为一代乳腺CT设备,IzoView正在为商业化而开发,截至本新闻稿发布之日,IzoView尚未在美国进行所需的临床研究以获得市场授权,也尚未获准在美国销售。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问